Loading
A phase 2 trial of Docetaxel, Pertuzumab, Trastuzumab, Trastuzumab emtansine and Atezolizumab in advanced solid tumours, run by Genentech, Inc., active and no longer recruiting.
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies is a phase 2 interventional study registered as NCT00781612 by Genentech, Inc., with 378 participants enrolled, started 2008-10-16 and due to reach its primary completion in 2027-06-30. Interventions recorded: Docetaxel, Paclitaxel, Pertuzumab, Trastuzumab, Trastuzumab Emtansine and Atezolizumab.
Shares Flatiron Health (Roche), Pertuzumab, Trastuzumab, Monoclonal antibodies and the tag pipeline.
Shares Flatiron Health (Roche), Trastuzumab emtansine, Atezolizumab, Trastuzumab and the tag pipeline.
Shares Pertuzumab, Trastuzumab, Docetaxel, Monoclonal antibodies and the tag pipeline.
Shares Pertuzumab, Monoclonal antibodies, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Flatiron Health (Roche), Atezolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Flatiron Health (Roche), Docetaxel, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Trastuzumab, Monoclonal antibodies, Metastatic cancer (cancer that has spread), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Flatiron Health (Roche), Atezolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.